{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:16:08Z","timestamp":1791922568437,"version":"4.3.4"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The activation of antigen specific T cells during an immune response is a tightly regulated process at the level of both costimulatory and coinhibitory receptors. One such coinhibitory receptor or checkpoint inhibitor which has received much attention in the field of oncology is the programmed cell death protein 1 (PD-1). Blockade of PD-1 or its ligand PD-L1 has proven successful in the treatment of a wide variety of cancers, therefore highlighting an important role for this pathway in anti-tumour immune responses. However, a caveat of PD-1 therapy and boosting anti-tumour immune responses is the development of self-reactive T cells which can lead to the induction of various autoimmune or inflammatory diseases, referred to as immune- related adverse events (irAEs). The emergence of rheumatological irAEs such as Inflammatory Arthritis (IA) in recent years has highlighted the importance of PD-1 in maintaining self-tolerance. Furthermore, the emergence of rheumatology related irAEs raises an important question as to how defects in this pathway can contribute to spontaneous rheumatological disease. In this review, we describe the biological distribution, function and regulation of the PD-1 pathway, its potential role in IA and irAE related IA.<\/jats:p>","DOI":"10.1186\/s41927-020-00171-2","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:03:54Z","timestamp":1610323434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["The PD-1:PD-L1 axis in Inflammatory Arthritis"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-2563","authenticated-orcid":false,"given":"Mary","family":"Canavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilleas","family":"Floudas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Veale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Fearon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"171_CR1","doi-asserted-by":"crossref","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. NIH Public Access. 2013;13:227\u201342. Available from: https:\/\/www.pmc\/articles\/PMC3786574\/?report=abstract. [cited\u00a02020 Aug 12].","DOI":"10.1038\/nri3405"},{"key":"171_CR2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18173375\/. [cited 2020 Aug 12].","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"171_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765\u201372.","journal-title":"Int Immunol"},{"key":"171_CR4","doi-asserted-by":"crossref","unstructured":"Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229:114\u201325. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19426218. [cited 2020 Mar 28].","DOI":"10.1111\/j.1600-065X.2009.00767.x"},{"issue":"7077","key":"171_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682\u20137 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16382236. [cited 2020 Mar 28].","journal-title":"Nature"},{"key":"171_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265\u201376 Elsevier Ltd.","journal-title":"Trends Immunol"},{"key":"171_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399 Nature Publishing Group.","journal-title":"Nat Rev Immunol"},{"key":"171_CR8","doi-asserted-by":"crossref","unstructured":"Ghiotto M, Gauthier L, Serriari N, Pastor S, Truneh A, Nun\u00e8s JA, et al. PD-L1 and\u00a0PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol.\u00a02010;22(8):651\u201360.\u00a0Available from:\u00a0https:\/\/academic.oup.com\/intimm\/article-abstract\/22\/8\/651\/774506.\u00a0[cited 2020 Mar 29].","DOI":"10.1093\/intimm\/dxq049"},{"issue":"10","key":"171_CR9","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","volume":"169","author":"T Yamazaki","year":"2002","unstructured":"Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of Programmed Death 1 Ligands by Murine T Cells and APC. J Immunol. 2002;169(10):5538\u201345 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12421930\/, [cited 2020 Jul 29].","journal-title":"J Immunol"},{"issue":"3","key":"171_CR10","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","volume":"170","author":"JA Brown","year":"2003","unstructured":"Brown JA, Dorfman DM, Ma F-R, Sullivan EL, Munoz O, Wood CR, et al. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production. J Immunol. 2003;170(3):1257\u201366 Available from: http:\/\/www.jimmunol.org\/content\/170\/3\/1257. http:\/\/www.jimmunol.org\/content\/170\/3\/1257.full#ref-list-1. [cited 2020 Jul 29].","journal-title":"J Immunol"},{"issue":"5","key":"171_CR11","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nm863","volume":"9","author":"TJ Curiel","year":"2003","unstructured":"Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562\u20137 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12704383\/. [cited 2020 Jul 29].","journal-title":"Nat Med"},{"key":"171_CR12","doi-asserted-by":"publisher","unstructured":"Karakhanova S, Meisel S, Ring S, Mahnke K, Enk AH. ERK\/p38 MAP-kinases and PI3K are involved in the differential regulation of B7-H1 expression in DC subsets. Eur J Immunol. 2009 ;40(1):254\u2013266. Available from: https:\/\/doi.org\/10.1002\/eji.200939289. [cited 2020 Jul 29].","DOI":"10.1002\/eji.200939289"},{"key":"171_CR13","doi-asserted-by":"publisher","unstructured":"Karakhanova S, Bedke T, Enk AH, Mahnke K. IL-27 renders DC immunosuppressive by induction of B7-H1. J Leukoc Biol. 2011 ;89(6):837\u2013845. Available from: https:\/\/doi.org\/10.1189\/jlb.1209788. [cited 2020 Jul 29].","DOI":"10.1189\/jlb.1209788"},{"issue":"4","key":"171_CR14","doi-asserted-by":"publisher","first-page":"e61602","DOI":"10.1371\/journal.pone.0061602","volume":"8","author":"G Huang","year":"2013","unstructured":"Huang G, Wen Q, Zhao Y, Gao Q, Bai Y. NF-\u03baB Plays a Key Role in Inducing CD274 Expression in Human Monocytes after Lipopolysaccharide Treatment. Viola JPB, editor. PLoS One. 2013;8(4):e61602 Available from: https:\/\/dx.plos.org\/10.1371\/journal.pone.0061602. [cited 2020 Jul 29].","journal-title":"PLoS One"},{"issue":"5","key":"171_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781\u201390 Available from: www.jem.org\/cgi\/doi\/10.1084\/jem.20131916. [cited 2020 Jul 29].","journal-title":"J Exp Med"},{"issue":"52","key":"171_CR16","doi-asserted-by":"publisher","first-page":"20852","DOI":"10.1073\/pnas.0810958105","volume":"105","author":"M Marzec","year":"2008","unstructured":"Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008;105(52):20852\u20137 Available from: www.pnas.org\/cgi\/doi\/10.1073\/pnas.0810958105. [cited 2020 Jul 29].","journal-title":"Proc Natl Acad Sci U S A"},{"key":"171_CR17","doi-asserted-by":"crossref","unstructured":"Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, et al. TLR3-Stimulated Dendritic Cells Up-regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor Vaccination. J Immunol. 2009 183(6):3634\u20133641. Available from: www.jimmunol.org\/cgi\/doi\/10.4049\/jimmunol.0900974. [cited 2020 Jul 29].","DOI":"10.4049\/jimmunol.0900974"},{"issue":"7670","key":"171_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature23669","volume":"549","author":"R Mezzadra","year":"2017","unstructured":"Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, De Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549(7670):106\u201310 Available from: https:\/\/www.nature.com\/articles\/nature23669. [cited 2020 Jul 29].","journal-title":"Nature"},{"issue":"8","key":"171_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/intimm\/dxq049","volume":"22","author":"M Ghiotto","year":"2010","unstructured":"Ghiotto M, Gauthier L, Serriari N, Pastor S, Truneh A, Nun\u00e8 JA, et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol. 2010;22(8):651\u201360 Available from: https:\/\/academic.oup.com\/intimm\/article-abstract\/22\/8\/651\/774506. [cited 2020 Mar 29].","journal-title":"Int Immunol"},{"issue":"3","key":"171_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","volume":"20","author":"X Zhang","year":"2004","unstructured":"Zhang X, Schwartz JCD, Guo X, Bhatia S, Cao E, Chen L, et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004;20(3):337\u201347.","journal-title":"Immunity."},{"issue":"6","key":"171_CR21","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1128\/MCB.14.6.3729","volume":"14","author":"LK Gauen","year":"1994","unstructured":"Gauen LK, Zhu Y, Letourneur F, Hu Q, Bolen JB, Matis LA, et al. Interactions of p59fyn and ZAP-70 with T-cell receptor activation motifs: defining the nature of a signalling motif. Mol Cell Biol. 1994;14(6):3729\u201341.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"171_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0092-8674(92)90428-F","volume":"70","author":"DB Straus","year":"1992","unstructured":"Straus DB, Weiss A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell. 1992;70(4):585\u201393.","journal-title":"Cell."},{"issue":"12","key":"171_CR23","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","volume":"23","author":"KM Zak","year":"2015","unstructured":"Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, et al. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure. 2015;23(12):2341\u20138.","journal-title":"Structure."},{"issue":"2","key":"171_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. J Immunol. 2004;173(2):945\u201354.","journal-title":"J Immunol"},{"issue":"1\u20133","key":"171_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","volume":"574","author":"KA Sheppard","year":"2004","unstructured":"Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3\u03b6 signalosome and downstream signaling to PKC\u03b8. FEBS Lett. 2004;574(1\u20133):37\u201341.","journal-title":"FEBS Lett"},{"key":"171_CR26","doi-asserted-by":"crossref","unstructured":"Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory\u00a0receptor CD28 is a primary target for PD-1-mediated inhibition. Science (80-). 2017;355(6332):1428\u201333.","DOI":"10.1126\/science.aaf1292"},{"issue":"29","key":"171_CR27","doi-asserted-by":"publisher","first-page":"10691","DOI":"10.1073\/pnas.0307252101","volume":"101","author":"YE Latchman","year":"2004","unstructured":"Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A. 2004;101(29):10691\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"171_CR28","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med"},{"key":"171_CR29","doi-asserted-by":"publisher","unstructured":"Gato-Ca\u00f1as M, Zuazo M, Arasanz H, Iba\u00f1ez-Vea M, Lorenzo L, Fernandez-Hinojal G, et al. PD-L1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Rep. 2017;20(8):1818\u201329. Available from: https:\/\/doi.org\/10.1016\/j.celrep.2017.07.075. [cited 2020 Jul 29].","DOI":"10.1016\/j.celrep.2017.07.075"},{"issue":"9","key":"171_CR30","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1002\/eji.200635978","volume":"36","author":"H Kuipers","year":"2006","unstructured":"Kuipers H, Muskens F, Willart M, Hijdra D, van Assema FBJ, Coyle AJ, et al. Contribution of the PD-1 ligands\/PD-1 signaling pathway to dendritic cell-mediated CD4+ cell activation. Eur J Immunol. 2006;36(9):2472\u201382.","journal-title":"Eur J Immunol."},{"issue":"3","key":"171_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1172\/JCI16015","volume":"111","author":"H Dong","year":"2003","unstructured":"Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. 2003;111(3):363\u201370.","journal-title":"J Clin Invest"},{"issue":"7","key":"171_CR32","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","volume":"181","author":"KJ Oestreich","year":"2008","unstructured":"Oestreich KJ, Yoon H, Ahmed R, Boss JM. NFATc1 Regulates PD-1 Expression upon T Cell Activation. J Immunol. 2008;181(7):4832\u20139.","journal-title":"J Immunol"},{"issue":"1","key":"171_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/icb.2012.53","volume":"91","author":"M Mathieu","year":"2013","unstructured":"Mathieu M, Cotta-Grand N, Daudelin JF, Th\u00e9bault P, Labrecque N. Notch signaling regulates PD-1 expression during CD8+ T-cell activation. Immunol Cell Biol. 2013;91(1):82\u20138.","journal-title":"Immunol Cell Biol."},{"issue":"3","key":"171_CR34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2012.01.015","volume":"36","author":"RR Rao","year":"2012","unstructured":"Rao RR, Li Q, Bupp MRG, Shrikant PA. Transcription Factor Foxo1 Represses T-bet-Mediated Effector Functions and Promotes Memory CD8\u2009+\u2009T Cell Differentiation. Immunity. 2012;36(3):374\u201387.","journal-title":"Immunity."},{"issue":"7","key":"171_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ni.2046","volume":"12","author":"C Kao","year":"2011","unstructured":"Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MAA, et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol. 2011;12(7):663\u201371.","journal-title":"Nat Immunol"},{"key":"171_CR36","doi-asserted-by":"crossref","unstructured":"Bally APR, Lu P, Tang Y, Austin JW, Scharer CD, Ahmed R, et al. NF-\u03baB Regulates\u00a0PD-1 Expression in Macrophages. J Immunol. 2015;194(9):4545\u201354. Available from: http:\/\/www.jimmunol.org\/content\/194\/9\/4545. [cited 2020 Mar\u00a029].","DOI":"10.4049\/jimmunol.1402550"},{"key":"171_CR37","doi-asserted-by":"crossref","unstructured":"Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O\u2019Shea MA, et al. The\u00a0Common \u03b3-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of\u00a0Programmed Death-1 and Its Ligands [Internet]. J Immunol. 2008;181. Available from: https:\/\/www.jimmunol.org. [cited 2020 Mar 29].","DOI":"10.4049\/jimmunol.181.10.6738"},{"issue":"8","key":"171_CR38","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-14-3016","volume":"75","author":"Z Sun","year":"2015","unstructured":"Sun Z, Fourcade J, Pagliano O, Chauvin JM, Sander C, Kirkwood JM, et al. IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells. Cancer Res. 2015;75(8):1635\u201344.","journal-title":"Cancer Res"},{"issue":"12","key":"171_CR39","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/2159-8290.CD-15-1347","volume":"6","author":"BV Park","year":"2016","unstructured":"Park BV, Freeman ZT, Ghasemzadeh A, Chattergoon MA, Rutebemberwa A, Steigner J, et al. TGF\u03b21-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer. Cancer Discov. 2016;6(12):1366\u201381.","journal-title":"Cancer Discov"},{"issue":"2","key":"171_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141\u201351.","journal-title":"Immunity."},{"issue":"5","key":"171_CR41","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1084\/jem.191.5.891","volume":"191","author":"H Nishimura","year":"2000","unstructured":"Nishimura H, Honjo T, Minato N. Facilitation of \u03b2 selection and modification of positive selection in the thymus of PD-1-deficient mice. J Exp Med. 2000;191(5):891\u20137.","journal-title":"J Exp Med."},{"issue":"7","key":"171_CR42","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.celrep.2016.10.042","volume":"17","author":"TT Jiang","year":"2016","unstructured":"Jiang TT, Martinov T, Xin L, Kinder JM, Spanier JA, Fife BT, et al. Programmed Death-1 Culls Peripheral Accumulation of High-Affinity Autoreactive CD4 T Cells to Protect against Autoimmunity. Cell Rep. 2016;17(7):1783\u201394.","journal-title":"Cell Rep."},{"issue":"2","key":"171_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.immuni.2013.11.017","volume":"40","author":"T Honda","year":"2014","unstructured":"Honda T, Egen JG, L\u00e4mmermann T, Kastenm\u00fcller W, Torabi-Parizi P, Germain RN. Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues. Immunity. 2014;40(2):235\u201347.","journal-title":"Immunity."},{"issue":"11","key":"171_CR44","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ni.1790","volume":"10","author":"BT Fife","year":"2009","unstructured":"Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009;10(11):1185\u201392.","journal-title":"Nat Immunol."},{"issue":"12","key":"171_CR45","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1084\/jem.20061577","volume":"203","author":"BT Fife","year":"2006","unstructured":"Fife BT, Guleria I, Bupp MG, Eagar TN, Tang Q, Bour-Jordan H, et al. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med. 2006;203(12):2737\u201347.","journal-title":"J Exp Med."},{"issue":"18","key":"171_CR46","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1073\/pnas.1718217115","volume":"115","author":"E Ahn","year":"2018","unstructured":"Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, et al. Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci U S A. 2018;115(18):4749\u201354.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"8","key":"171_CR47","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.4049\/jimmunol.1402262","volume":"194","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Nelson CE, Martinov T, Spanier JA, Heffernan JR, Sahli NL, et al. Cutting Edge: Identification of Autoreactive CD4 + and CD8 + T Cell Subsets Resistant to PD-1 Pathway Blockade. J Immunol. 2015;194(8):3551\u20135.","journal-title":"J Immunol."},{"key":"171_CR48","doi-asserted-by":"crossref","unstructured":"Roncador G, Brown PJ, Maestre L, Hue S, Mart\u00ednez-Torrecuadrada JL, Ling KL, et al.\u00a0Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the\u00a0single-cell level. Eur J Immunol. 2005;35(6):1681\u201391. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15902688\/.\u00a0[cited 2020 Aug 12].","DOI":"10.1002\/eji.200526189"},{"key":"171_CR49","doi-asserted-by":"crossref","unstructured":"Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015\u201329. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20008522\/. [cited 2020 Aug 12].","DOI":"10.1084\/jem.20090847"},{"key":"171_CR50","doi-asserted-by":"crossref","unstructured":"Amarnath S, Mangus CW, Wang JCM, Wei F, He A, Kapoor V, et al. The PDL1-PD1\u00a0axis converts human T H1 cells into regulatory T cells. Sci Transl Med. 2011;3(111):111ra120. Available from: https:\/\/www.pmc\/articles\/PMC3235958\/?report=abstract.\u00a0[cited 2020 Aug 12].","DOI":"10.1126\/scitranslmed.3003130"},{"key":"171_CR51","doi-asserted-by":"crossref","unstructured":"Gotot J, Gottschalk C, Leopold S, Knolle PA, Yagita H, Kurts C, et al. Regulatory T\u00a0cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo.\u00a0Proc Natl Acad Sci U S A. 2012;109(26):10468\u201373. Available from: https:\/\/www.pmc\/articles\/PMC3387068\/?report=abstract.\u00a0[cited 2020 Aug 12].","DOI":"10.1073\/pnas.1201131109"},{"key":"171_CR52","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495\u20139.","journal-title":"Nature."},{"key":"171_CR53","doi-asserted-by":"crossref","unstructured":"Lim TS, Chew V, Sieow JL, Goh S, Yeong JPS, Soon AL, et al. PD-1 expression on\u00a0dendritic cells suppresses CD8+T cell function and antitumor immunity.\u00a0Oncoimmunology. 2016;5(3).","DOI":"10.1080\/2162402X.2015.1085146"},{"key":"171_CR54","doi-asserted-by":"crossref","unstructured":"Zhao Y, Harrison DL, Song Y, Ji J, Huang J, Hui E. Antigen-Presenting Cell-Intrinsic\u00a0PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. Cell Rep. 2018.","DOI":"10.1016\/j.celrep.2018.06.054"},{"issue":"24","key":"171_CR55","doi-asserted-by":"publisher","first-page":"13866","DOI":"10.1073\/pnas.231486598","volume":"98","author":"T Okazaki","year":"2001","unstructured":"Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001;98(24):13866\u201371.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"171_CR56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.molimm.2019.02.009","volume":"109","author":"X Wang","year":"2019","unstructured":"Wang X, Wang G, Wang Z, Liu B, Han N, Li J, et al. PD-1-expressing B cells suppress CD4 + and CD8 + T cells via PD-1\/PD-L1-dependent pathway. Mol Immunol. 2019;109:20\u20136.","journal-title":"Mol Immunol."},{"issue":"9","key":"171_CR57","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1089\/ars.2008.2400","volume":"11","author":"KM Oliver","year":"2009","unstructured":"Oliver KM, Garvey JF, Ng CT, Veale DJ, Fearon U, Cummins EP, et al. Hypoxia activates NF-\u03baB-dependent gene expression through the canonical signaling pathway. Antioxid Redox Signal. 2009;11(9):2057\u201364.","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"171_CR58","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1136\/annrheumdis-2013-204105","volume":"74","author":"W Gao","year":"2015","unstructured":"Gao W, McCormick J, Connolly M, Balogh E, Veale DJ, Fearon U. Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1275\u201383 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24525913.","journal-title":"Ann Rheum Dis"},{"key":"171_CR59","doi-asserted-by":"publisher","unstructured":"Gao W, Sweeney C, Connolly M, Kennedy A, Ng CT, McCormick J, et al. Notch-1 mediates hypoxia-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum. 2012;64(7):2104\u201313. Available from: https:\/\/doi.org\/10.1002\/art.34397. [cited 2020 Mar 26].","DOI":"10.1002\/art.34397"},{"issue":"1","key":"171_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6(1):1\u201313.","journal-title":"Nat Commun"},{"issue":"2","key":"171_CR61","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","volume":"45","author":"B Bengsch","year":"2016","unstructured":"Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, et al. Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8+ T Cell Exhaustion. Immunity. 2016;45(2):358\u201373.","journal-title":"Immunity."},{"key":"171_CR62","doi-asserted-by":"crossref","unstructured":"Ogando J, Sa\u00e9z ME, Santos J, Nuevo-Tapioles C, Gut M, Esteve-Codina A, et al. PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8+ T lymphocytes. J Immunother Cancer. 2019;7(1).","DOI":"10.1186\/s40425-019-0628-7"},{"key":"171_CR63","doi-asserted-by":"crossref","unstructured":"Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X, et al. Immune\u00a0checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of\u00a0rheumatoid arthritis disease progression. PLoS One. 2018;13(2).","DOI":"10.1371\/journal.pone.0192704"},{"key":"171_CR64","doi-asserted-by":"crossref","unstructured":"Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et\u00a0al. The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human\u00a0and murine arthritis. Arthritis Rheum. 2010;62(7):1870\u201380. Available from: http:\/\/doi.wiley.com\/10.1002\/art.27500. [cited 2020 Mar\u00a02].","DOI":"10.1002\/art.27500"},{"issue":"3","key":"171_CR65","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/cei.12949","volume":"188","author":"D Bommarito","year":"2017","unstructured":"Bommarito D, Hall C, Taams LS, Corrigall VM. Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol. 2017;188(3):455\u201366.","journal-title":"Clin Exp Immunol."},{"key":"171_CR66","doi-asserted-by":"crossref","unstructured":"Greisen SR, Yan Y, Hansen AS, Ven\u00f8 MT, Nyengaard JR, Moestrup SK, et al.\u00a0Extracellular vesicles transfer the receptor programmed death-1 in rheumatoid arthritis.\u00a0Front Immunol. 2017;8(JUL).","DOI":"10.3389\/fimmu.2017.00851"},{"issue":"12","key":"171_CR67","doi-asserted-by":"publisher","first-page":"8844","DOI":"10.4049\/jimmunol.177.12.8844","volume":"177","author":"B Wan","year":"2006","unstructured":"Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant Regulation of Synovial T Cell Activation by Soluble Costimulatory Molecules in Rheumatoid Arthritis. J Immunol. 2006;177(12):8844\u201350 Available from: http:\/\/www.jimmunol.org\/lookup\/doi\/10.4049\/jimmunol.177.12.8844. [cited 2019 Nov 13].","journal-title":"J Immunol"},{"key":"171_CR68","doi-asserted-by":"crossref","unstructured":"Moret FM, van der Wurff-Jacobs KMG, Bijlsma JWJ, Lafeber FPJG, van Roon JAG.\u00a0Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by\u00a0preventing PD-1\/PD-L1 interactions. Arthritis Res Ther. 2014;16(6).","DOI":"10.1186\/s13075-014-0497-x"},{"issue":"2","key":"171_CR69","first-page":"3297","volume":"17","author":"Q Luo","year":"2018","unstructured":"Luo Q, Ye J, Zeng L, Luo Z, Deng Z, Li X, et al. Elevated expression of PD-1 on T cells correlates with disease activity in rheumatoid arthritis. Mol Med Rep. 2018;17(2):3297\u2013305.","journal-title":"Mol Med Rep"},{"issue":"7","key":"171_CR70","first-page":"1410","volume":"30","author":"S Hatachi","year":"2003","unstructured":"Hatachi S, Iwai Y, Kawano S, Morinobu S, Kobayashi M, Koshiba M, et al. CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol. 2003;30(7):1410\u20139.","journal-title":"J Rheumatol."},{"issue":"1","key":"171_CR71","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s10753-013-9718-8","volume":"37","author":"S Li","year":"2014","unstructured":"Li S, Liao W, Chen M, Shan S, Song Y, Zhang S, et al. Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis. Inflammation. 2014;37(1):116\u201321.","journal-title":"Inflammation."},{"issue":"4","key":"171_CR72","doi-asserted-by":"publisher","first-page":"344","DOI":"10.5114\/ada.2018.75609","volume":"35","author":"J Bartosi\u0144ska","year":"2018","unstructured":"Bartosi\u0144ska J, Zakrzewska E, Purkot J, Michalak-Stoma A, Kowal M, Krasowska D, et al. Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis. Postep Dermatologii i Alergol. 2018;35(4):344\u201350.","journal-title":"Postep Dermatologii i Alergol."},{"issue":"4","key":"171_CR73","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/art.20966","volume":"52","author":"EKP Kong","year":"2005","unstructured":"Kong EKP, Prokunina-Olsson L, Wong WHS, Lau CS, Chan TM, Alarc\u00f3n-Riquelme M, et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum. 2005;52(4):1058\u201362.","journal-title":"Arthritis Rheum."},{"issue":"6440","key":"171_CR74","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1126\/science.aav7062","volume":"364","author":"D Sugiura","year":"2019","unstructured":"Sugiura D, Maruhashi T, Okazaki IM, Shimizu K, Maeda TK, Takemoto T, et al. Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses. Science (80-). 2019;364(6440):558\u201366.","journal-title":"Science (80-)"},{"key":"#cr-split#-171_CR75.1","doi-asserted-by":"crossref","unstructured":"Canavan M, Walsh AM, Bhargava V, Wade SM, McGarry T, Marzaioli V, et al. Enriched Cd141+ DCs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis. JCI Insight. 2018;3","DOI":"10.1172\/jci.insight.95228"},{"key":"#cr-split#-171_CR75.2","unstructured":"(23) Available from: https:\/\/insight.jci.org\/articles\/view\/95228. [cited 2019 Jun 19]."},{"key":"171_CR76","doi-asserted-by":"crossref","unstructured":"Petrelli A, Mijnheer G, Hoytema Van Konijnenburg DP, Van Der Wal MM,\u00a0Giovannone B, Mocholi E, et al. PD-1+CD8+ T cells are clonally expanding effectors\u00a0in human chronic inflammation. J Clin Invest. 2018;128(10):4669\u201381.","DOI":"10.1172\/JCI96107"},{"key":"171_CR77","doi-asserted-by":"crossref","unstructured":"Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2019.","DOI":"10.1136\/annrheumdis-2019-216109"},{"issue":"10","key":"171_CR78","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","volume":"76","author":"R Belkhir","year":"2017","unstructured":"Belkhir R, Le Burel S, Dunogeant L, Marabelle A, Hollebecque A, Besse B, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76(10):1747\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"171_CR79","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/art.38282","volume":"66","author":"BL Goldstein","year":"2014","unstructured":"Goldstein BL, Gedmintas L, Todd DJ. Concise communication. Arthritis Rheumatol. 2014;66(3):768\u20139.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"171_CR80","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43\u201350.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"171_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000412","volume":"3","author":"C Calabrese","year":"2017","unstructured":"Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity. RMD Open. 2017;3(1):e000412.","journal-title":"RMD Open"},{"issue":"2","key":"171_CR82","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","volume":"67","author":"K Buder-Bakhaya","year":"2018","unstructured":"Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF, et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother. 2018;67(2):175\u201382.","journal-title":"Cancer Immunol Immunother."},{"issue":"3","key":"171_CR83","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","volume":"77","author":"M Kostine","year":"2018","unstructured":"Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393\u20138.","journal-title":"Ann Rheum Dis."},{"key":"171_CR84","doi-asserted-by":"publisher","unstructured":"Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, et al. Clinical\u00a0presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by\u00a0immunotherapy regimen. Semin Arthritis Rheum. 2018;48(3):553\u20137. Available from: https:\/\/doi.org\/10.1016\/j.semarthrit.2018.02.011. [cited 2020 Apr\u00a09].","DOI":"10.1016\/j.semarthrit.2018.02.011"},{"issue":"3","key":"171_CR85","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","volume":"17","author":"M Lidar","year":"2018","unstructured":"Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018;17(3):284\u20139.","journal-title":"Autoimmun Rev."},{"key":"171_CR86","doi-asserted-by":"crossref","unstructured":"Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related\u00a0adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Med. 2015;13(1).","DOI":"10.1186\/s12916-015-0455-8"},{"issue":"5","key":"171_CR87","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","volume":"38","author":"J Roberts","year":"2019","unstructured":"Roberts J, Smylie M, Walker J, Basappa NS, Chu Q, Kolinsky M, et al. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor\u2013induced inflammatory arthritis. Clin Rheumatol. 2019;38(5):1513\u20139.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"171_CR88","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","volume":"76","author":"ST Kim","year":"2017","unstructured":"Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76(12):2061\u20134.","journal-title":"Ann Rheum Dis."},{"key":"171_CR89","doi-asserted-by":"publisher","unstructured":"Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, et al. Prophylactic\u00a0TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1\u00a0immunotherapy. Nature.\u00a02019;569(7756):428\u201332. Available from: https:\/\/doi.org\/10.1038\/s41586-019-1162-y.\u00a0[cited 2020 Aug 7].","DOI":"10.1038\/s41586-019-1162-y"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-020-00171-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-020-00171-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-020-00171-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:34:29Z","timestamp":1697535269000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-020-00171-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["171"],"URL":"https:\/\/doi.org\/10.1186\/s41927-020-00171-2","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Corresponding author Mary Canavan is an associate editor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}